Active Ingredient(s): Vorinostat
FDA Approved: * October 6, 2006
Pharm Company: * MERCK
Category: Cancer

Vorinostat (rINN)[3] also known as Suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. Vorinostat is marketed under the name Zolinza (/zolnz/ zoh-LIN-z) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Zolinza 100 mg Oral Capsule
NDC: 0006-0568
Merck Sharp & Dohme Corp.